,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2020', 'fs': 'Dec 2020', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CNY3m2AH'}, 'Id': 'a0POZ00000CNY3m2AH', 'Event_Date__c': '2020-12-04', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Dec 2020', 'Status_History__c': 'a132P000000CPhFQAW'}, 'change': None}]",Dec 2020,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2020', 'fs': 'Dec 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CNY3n2AH'}, 'Id': 'a0POZ00000CNY3n2AH', 'Event_Date__c': '2020-12-04', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Dec 2020', 'Status_History__c': 'a132P000000CPhKQAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2022', 'fs': 'May 2022', 'change': None}, 'Event_Description': {'s': 'Assigned to Cardiovascular Advisory Committee meeting to provide advice on Wednesday 8 June 2022', 'fs': 'Assigned to Cardiovascular Advisory Committee meeting to provide advice on Wednesday 8 June 2022', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CNY3o2AH'}, 'Id': 'a0POZ00000CNY3o2AH', 'Event_Date__c': '2022-05-05', 'Event_Description__c': 'Assigned to Cardiovascular Advisory Committee meeting to provide advice on Wednesday 8 June 2022', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'May 2022', 'Status_History__c': 'a132P000000DzHOQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee <strong>recommended</strong> that prasugrel for the treatment of acute coronary syndrome (ACS), ST elevation myocardial infarct or non-ST elevation myocardial infarct (STEMI or non-STEMI) be listed with a <strong>high priority</strong>. subject to the following Special Authority criteria:</p><p><strong style=""font-size: 9pt;"">PRASUGREL</strong></p><p><strong style=""font-size: 9pt;"">Initial application – Acute coronary syndrome</strong></p><p><span style=""font-size: 9pt;"">Applications from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has recently (within the last 60 days) been diagnosed with an ST-elevation or non-ST-elevation acute coronary syndrome; and</span></p><p><span style=""font-family: Calibri, sans-serif;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Fibrinolytic therapy has not been given in the last 24 hours and is not planned</span></p><p><span style=""font-family: Calibri, sans-serif;"">\xa0</span></p><p><strong style=""font-size: 9pt;"">Renewal – Acute coronary syndrome</strong></p><p><span style=""font-size: 9pt;"">Applications from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has recently (within the last 60 days) been diagnosed with an ST-elevation or non-ST-elevation acute coronary syndrome; and</span></p><p><span style=""font-family: Calibri, sans-serif; font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Fibrinolytic therapy has not been given in the last 24 hours and is not planned</span></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Committee considered: </p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The high health need and severe impact of ACS on the patient and their family/whānau;</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The high prevalence of ACS affecting Māori and Pacific peoples;</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The demonstrated non-inferiority of prasugrel over ticagrelor for the treatment of patients after ACS.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The evidence that prasugrel provides a health benefit in reducing all-cause mortality, subsequent myocardial infarction in those with ACS; and</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The suitability benefit of once daily dosing with prasugrel over alternative post ASC treatments, which may result in improved adherence and would be likely to have a pro-equity impact</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee <strong>recommended</strong> that prasugrel for the treatment of acute coronary syndrome (ACS), ST elevation myocardial infarct or non-ST elevation myocardial infarct (STEMI or non-STEMI) be listed with a <strong>high priority</strong>. subject to the following Special Authority criteria:</p><p><strong style=""font-size: 9pt;"">PRASUGREL</strong></p><p><strong style=""font-size: 9pt;"">Initial application – Acute coronary syndrome</strong></p><p><span style=""font-size: 9pt;"">Applications from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has recently (within the last 60 days) been diagnosed with an ST-elevation or non-ST-elevation acute coronary syndrome; and</span></p><p><span style=""font-family: Calibri, sans-serif;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Fibrinolytic therapy has not been given in the last 24 hours and is not planned</span></p><p><span style=""font-family: Calibri, sans-serif;"">\xa0</span></p><p><strong style=""font-size: 9pt;"">Renewal – Acute coronary syndrome</strong></p><p><span style=""font-size: 9pt;"">Applications from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has recently (within the last 60 days) been diagnosed with an ST-elevation or non-ST-elevation acute coronary syndrome; and</span></p><p><span style=""font-family: Calibri, sans-serif; font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Fibrinolytic therapy has not been given in the last 24 hours and is not planned</span></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Committee considered: </p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The high health need and severe impact of ACS on the patient and their family/whānau;</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The high prevalence of ACS affecting Māori and Pacific peoples;</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The demonstrated non-inferiority of prasugrel over ticagrelor for the treatment of patients after ACS.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The evidence that prasugrel provides a health benefit in reducing all-cause mortality, subsequent myocardial infarction in those with ACS; and</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The suitability benefit of once daily dosing with prasugrel over alternative post ASC treatments, which may result in improved adherence and would be likely to have a pro-equity impact</p>', 'change': None}, 'Published_Discussion': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee noted that prasugrel has previously been listed on the Pharmaceutical Schedule subject to special authority criteria (for patients receiving coronary stenting and demonstrating a clopidogrel allergy/stent thrombosis while on clopidogrel) from April 2012 until it was delisted in January 2021 due to the supplier discontinuing distribution in New Zealand. The Committee noted that generic prasugrel products may be available for supply in the future.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that while there may not be an unmet health need in the context of post-ACS therapy with the availability of both clopidogrel and ticagrelor, it was noted that some patients may be intolerant of or contraindicated to both agents and thus have no suitable treatment options.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in the last full year of listing, 83 people were dispensed prasugrel and at the time Members of the Committee considered that ticagrelor was a reasonable funded alternative. </p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the health needs of those with ACS is severe and post event clinical management is critical to achieve favourable long-term outcomes, such as the avoidance of additional ACS and related events. The Committee noted that ACS is a significant cause of mortality, with significant inequity experienced by Māori and Pacific people who experience ACS at a younger age. The Committee noted that ACS is encompassed in the Māori health area of focus, Hauora Arotahi - Manawa Ora (Heart Health – high blood pressure and stroke), with Ischaemic Heart Disease (IHD) responsible for 40% of deaths in Māori under the age of 65 versus 10% for non-Māori. It is estimated that the one year post-ACS presentation, the mortality rate for Māori is 2.55 times that of non-Māori / non-Pacific populations (<a href=""https://journal.nzma.org.nz/journal-articles/inequity-in-one-year-mortality-after-first-myocardial-infarction-in-maori-and-pacific-patients-how-much-is-associated-with-differences-in-modifiable-clinical-risk-factors-anzacs-qi-49"" target=""_blank"">Mazengarb et al. NZMJ 2020;133:1521</a>). </p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the findings of the ISAR-REACT 5 trial (<a href=""https://www.nejm.org/doi/full/10.1056/NEJMoa1908973"" target=""_blank"">Schupke et al, N Engl J Med 2019;381:1524-34</a>), which included 4018 patients presenting with ACS who were randomised to either ticagrelor (n=2012) or prasugrel (n=2006) for a 12 month period. The Committee noted that the ISAR-REACT 5 trial was designed to show a benefit of ticagrelor over prasugrel in the treatment of patients post-ACS. The trial reported an advantage to prasugrel with regards to the composite endpoint of death any cause / myocardial infarction or stroke at one year with a hazard ratio for ticagrelor of 1.36 (95% CI 1.09 to 1.70 P&lt;0.006). It was also noted that the hazard ratio for death any cause for ticagrelor was 1.23 (95% CI 0.91-1.69) versus prasugrel, and the hazard ratio for ticagrelor for myocardial infarction was 1.63 (95% CI 1.18-2.25).</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the findings of the HOST_REDUCE_POLYTECH_ACS open label non-inferiority randomised controlled trial (<a href=""https://www.sciencedirect.com/science/article/pii/S0140673620317918"" target=""_blank"">Kim et al. Lancet 2020; 396:1079-89</a>), which randomised 2338 patients presenting with ACS to treatment with prasugrel using either a standard dose (n=1168) of 10 mg prasugrel + 100 mg aspirin for one year versus a de-escalation dose (n=1170) of 10 mg prasugrel + 100 mg aspirin for one month then 5 mg prasugrel + 100 mg aspirin for 11 months. The trial reported on Net Adverse Clinical Events defined as a composite of all-cause death, non-fatal MI, stent thrombosis and bleeding events BARC grade 2 or higher. The Committee noted that the trial reported a hazard ratio (HR) of 0.70 (CI 0.52-0.92) in favour of the de-escalation treatment arm. The Committee noted that the advantage of the de-escalation dosing strategy was particularly noticeable with the secondary safety end point of bleeding BARC type 2 or greater, where a HR of 0.48 (CI 0.32-0.73) was observed.</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the trial evidence demonstrated that prasugrel was at least as effective as ticagrelor in the treatment of patient post-ACS, with the advantage of having once daily dosing, which the Committee considered may result in improved treatment adherence over the required 12-month post-ACS treatment period.</p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence tabled in the HOST_REDUCE POLYTECH_ACS trial was impressive, demonstrating non-inferior primary efficacy with a significant reduction in on-treatment bleeding. However, the Committee noted that this was an open-label trial and that it was conducted on an East Asian population (Korean), and its results may or may not be realised in a New Zealand population to the same degree. </p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that both trials used objective endpoints of death, myocardial infarction (MI) and stroke. It was observed by some Members of the Committee that the period of the trials was only 12 months; however it was noted that there was no strong evidence available to support continued post-ACS dual anti-platelet therapy (DAPT) past 12 months.</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that most prescribers would likely favour the use of prasugrel over ticagrelor should it be made available on the Pharmaceutical Schedule.</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Advisory Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for prasugrel if it were to be funded in New Zealand for the treatment of acute coronary syndrome (ACS), ST elevation myocardial infarct or non-ST elevation myocardial infarct (STEMI or non-STEMI). This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000CNY3p&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000002ZNIl"" alt=""image.png""></img></p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee noted that prasugrel has previously been listed on the Pharmaceutical Schedule subject to special authority criteria (for patients receiving coronary stenting and demonstrating a clopidogrel allergy/stent thrombosis while on clopidogrel) from April 2012 until it was delisted in January 2021 due to the supplier discontinuing distribution in New Zealand. The Committee noted that generic prasugrel products may be available for supply in the future.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that while there may not be an unmet health need in the context of post-ACS therapy with the availability of both clopidogrel and ticagrelor, it was noted that some patients may be intolerant of or contraindicated to both agents and thus have no suitable treatment options.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in the last full year of listing, 83 people were dispensed prasugrel and at the time Members of the Committee considered that ticagrelor was a reasonable funded alternative. </p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the health needs of those with ACS is severe and post event clinical management is critical to achieve favourable long-term outcomes, such as the avoidance of additional ACS and related events. The Committee noted that ACS is a significant cause of mortality, with significant inequity experienced by Māori and Pacific people who experience ACS at a younger age. The Committee noted that ACS is encompassed in the Māori health area of focus, Hauora Arotahi - Manawa Ora (Heart Health – high blood pressure and stroke), with Ischaemic Heart Disease (IHD) responsible for 40% of deaths in Māori under the age of 65 versus 10% for non-Māori. It is estimated that the one year post-ACS presentation, the mortality rate for Māori is 2.55 times that of non-Māori / non-Pacific populations (<a href=""https://journal.nzma.org.nz/journal-articles/inequity-in-one-year-mortality-after-first-myocardial-infarction-in-maori-and-pacific-patients-how-much-is-associated-with-differences-in-modifiable-clinical-risk-factors-anzacs-qi-49"" target=""_blank"">Mazengarb et al. NZMJ 2020;133:1521</a>). </p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the findings of the ISAR-REACT 5 trial (<a href=""https://www.nejm.org/doi/full/10.1056/NEJMoa1908973"" target=""_blank"">Schupke et al, N Engl J Med 2019;381:1524-34</a>), which included 4018 patients presenting with ACS who were randomised to either ticagrelor (n=2012) or prasugrel (n=2006) for a 12 month period. The Committee noted that the ISAR-REACT 5 trial was designed to show a benefit of ticagrelor over prasugrel in the treatment of patients post-ACS. The trial reported an advantage to prasugrel with regards to the composite endpoint of death any cause / myocardial infarction or stroke at one year with a hazard ratio for ticagrelor of 1.36 (95% CI 1.09 to 1.70 P&lt;0.006). It was also noted that the hazard ratio for death any cause for ticagrelor was 1.23 (95% CI 0.91-1.69) versus prasugrel, and the hazard ratio for ticagrelor for myocardial infarction was 1.63 (95% CI 1.18-2.25).</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the findings of the HOST_REDUCE_POLYTECH_ACS open label non-inferiority randomised controlled trial (<a href=""https://www.sciencedirect.com/science/article/pii/S0140673620317918"" target=""_blank"">Kim et al. Lancet 2020; 396:1079-89</a>), which randomised 2338 patients presenting with ACS to treatment with prasugrel using either a standard dose (n=1168) of 10 mg prasugrel + 100 mg aspirin for one year versus a de-escalation dose (n=1170) of 10 mg prasugrel + 100 mg aspirin for one month then 5 mg prasugrel + 100 mg aspirin for 11 months. The trial reported on Net Adverse Clinical Events defined as a composite of all-cause death, non-fatal MI, stent thrombosis and bleeding events BARC grade 2 or higher. The Committee noted that the trial reported a hazard ratio (HR) of 0.70 (CI 0.52-0.92) in favour of the de-escalation treatment arm. The Committee noted that the advantage of the de-escalation dosing strategy was particularly noticeable with the secondary safety end point of bleeding BARC type 2 or greater, where a HR of 0.48 (CI 0.32-0.73) was observed.</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the trial evidence demonstrated that prasugrel was at least as effective as ticagrelor in the treatment of patient post-ACS, with the advantage of having once daily dosing, which the Committee considered may result in improved treatment adherence over the required 12-month post-ACS treatment period.</p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence tabled in the HOST_REDUCE POLYTECH_ACS trial was impressive, demonstrating non-inferior primary efficacy with a significant reduction in on-treatment bleeding. However, the Committee noted that this was an open-label trial and that it was conducted on an East Asian population (Korean), and its results may or may not be realised in a New Zealand population to the same degree. </p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that both trials used objective endpoints of death, myocardial infarction (MI) and stroke. It was observed by some Members of the Committee that the period of the trials was only 12 months; however it was noted that there was no strong evidence available to support continued post-ACS dual anti-platelet therapy (DAPT) past 12 months.</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that most prescribers would likely favour the use of prasugrel over ticagrelor should it be made available on the Pharmaceutical Schedule.</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Advisory Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for prasugrel if it were to be funded in New Zealand for the treatment of acute coronary syndrome (ACS), ST elevation myocardial infarct or non-ST elevation myocardial infarct (STEMI or non-STEMI). This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000CNY3p&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000002ZNIl"" alt=""image.png""></img></p>', 'change': None}, 'Published_Application': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee reviewed the application from a clinician for patients with an acute coronary syndrome (ACS), ST elevation myocardial infarct or non-ST elevation myocardial infarct (STEMI or non-STEMI).</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item. </p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee reviewed the application from a clinician for patients with an acute coronary syndrome (ACS), ST elevation myocardial infarct or non-ST elevation myocardial infarct (STEMI or non-STEMI).</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item. </p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2022', 'fs': 'Oct 2022', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cardiovascular Advisory Committee at meeting Wednesday 8 June 2022.', 'fs': 'Clinical advice received from Cardiovascular Advisory Committee at meeting Wednesday 8 June 2022.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CNY3p2AH'}, 'Id': 'a0POZ00000CNY3p2AH', 'Event_Date__c': '2022-10-17', 'Event_Description__c': 'Clinical advice received from Cardiovascular Advisory Committee at meeting Wednesday 8 June 2022.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'High', 'Formatted_Date__c': 'Oct 2022', 'Published_Recommendation__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee <strong>recommended</strong> that prasugrel for the treatment of acute coronary syndrome (ACS), ST elevation myocardial infarct or non-ST elevation myocardial infarct (STEMI or non-STEMI) be listed with a <strong>high priority</strong>. subject to the following Special Authority criteria:</p><p><strong style=""font-size: 9pt;"">PRASUGREL</strong></p><p><strong style=""font-size: 9pt;"">Initial application – Acute coronary syndrome</strong></p><p><span style=""font-size: 9pt;"">Applications from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has recently (within the last 60 days) been diagnosed with an ST-elevation or non-ST-elevation acute coronary syndrome; and</span></p><p><span style=""font-family: Calibri, sans-serif;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Fibrinolytic therapy has not been given in the last 24 hours and is not planned</span></p><p><span style=""font-family: Calibri, sans-serif;"">\xa0</span></p><p><strong style=""font-size: 9pt;"">Renewal – Acute coronary syndrome</strong></p><p><span style=""font-size: 9pt;"">Applications from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has recently (within the last 60 days) been diagnosed with an ST-elevation or non-ST-elevation acute coronary syndrome; and</span></p><p><span style=""font-family: Calibri, sans-serif; font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Fibrinolytic therapy has not been given in the last 24 hours and is not planned</span></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Committee considered: </p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The high health need and severe impact of ACS on the patient and their family/whānau;</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The high prevalence of ACS affecting Māori and Pacific peoples;</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The demonstrated non-inferiority of prasugrel over ticagrelor for the treatment of patients after ACS.</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The evidence that prasugrel provides a health benefit in reducing all-cause mortality, subsequent myocardial infarction in those with ACS; and</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The suitability benefit of once daily dosing with prasugrel over alternative post ASC treatments, which may result in improved adherence and would be likely to have a pro-equity impact</p>', 'Published_Application__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee reviewed the application from a clinician for patients with an acute coronary syndrome (ACS), ST elevation myocardial infarct or non-ST elevation myocardial infarct (STEMI or non-STEMI).</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item. </p>', 'Published_Discussion__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee noted that prasugrel has previously been listed on the Pharmaceutical Schedule subject to special authority criteria (for patients receiving coronary stenting and demonstrating a clopidogrel allergy/stent thrombosis while on clopidogrel) from April 2012 until it was delisted in January 2021 due to the supplier discontinuing distribution in New Zealand. The Committee noted that generic prasugrel products may be available for supply in the future.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that while there may not be an unmet health need in the context of post-ACS therapy with the availability of both clopidogrel and ticagrelor, it was noted that some patients may be intolerant of or contraindicated to both agents and thus have no suitable treatment options.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in the last full year of listing, 83 people were dispensed prasugrel and at the time Members of the Committee considered that ticagrelor was a reasonable funded alternative. </p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the health needs of those with ACS is severe and post event clinical management is critical to achieve favourable long-term outcomes, such as the avoidance of additional ACS and related events. The Committee noted that ACS is a significant cause of mortality, with significant inequity experienced by Māori and Pacific people who experience ACS at a younger age. The Committee noted that ACS is encompassed in the Māori health area of focus, Hauora Arotahi - Manawa Ora (Heart Health – high blood pressure and stroke), with Ischaemic Heart Disease (IHD) responsible for 40% of deaths in Māori under the age of 65 versus 10% for non-Māori. It is estimated that the one year post-ACS presentation, the mortality rate for Māori is 2.55 times that of non-Māori / non-Pacific populations (<a href=""https://journal.nzma.org.nz/journal-articles/inequity-in-one-year-mortality-after-first-myocardial-infarction-in-maori-and-pacific-patients-how-much-is-associated-with-differences-in-modifiable-clinical-risk-factors-anzacs-qi-49"" target=""_blank"">Mazengarb et al. NZMJ 2020;133:1521</a>). </p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the findings of the ISAR-REACT 5 trial (<a href=""https://www.nejm.org/doi/full/10.1056/NEJMoa1908973"" target=""_blank"">Schupke et al, N Engl J Med 2019;381:1524-34</a>), which included 4018 patients presenting with ACS who were randomised to either ticagrelor (n=2012) or prasugrel (n=2006) for a 12 month period. The Committee noted that the ISAR-REACT 5 trial was designed to show a benefit of ticagrelor over prasugrel in the treatment of patients post-ACS. The trial reported an advantage to prasugrel with regards to the composite endpoint of death any cause / myocardial infarction or stroke at one year with a hazard ratio for ticagrelor of 1.36 (95% CI 1.09 to 1.70 P&lt;0.006). It was also noted that the hazard ratio for death any cause for ticagrelor was 1.23 (95% CI 0.91-1.69) versus prasugrel, and the hazard ratio for ticagrelor for myocardial infarction was 1.63 (95% CI 1.18-2.25).</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the findings of the HOST_REDUCE_POLYTECH_ACS open label non-inferiority randomised controlled trial (<a href=""https://www.sciencedirect.com/science/article/pii/S0140673620317918"" target=""_blank"">Kim et al. Lancet 2020; 396:1079-89</a>), which randomised 2338 patients presenting with ACS to treatment with prasugrel using either a standard dose (n=1168) of 10 mg prasugrel + 100 mg aspirin for one year versus a de-escalation dose (n=1170) of 10 mg prasugrel + 100 mg aspirin for one month then 5 mg prasugrel + 100 mg aspirin for 11 months. The trial reported on Net Adverse Clinical Events defined as a composite of all-cause death, non-fatal MI, stent thrombosis and bleeding events BARC grade 2 or higher. The Committee noted that the trial reported a hazard ratio (HR) of 0.70 (CI 0.52-0.92) in favour of the de-escalation treatment arm. The Committee noted that the advantage of the de-escalation dosing strategy was particularly noticeable with the secondary safety end point of bleeding BARC type 2 or greater, where a HR of 0.48 (CI 0.32-0.73) was observed.</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the trial evidence demonstrated that prasugrel was at least as effective as ticagrelor in the treatment of patient post-ACS, with the advantage of having once daily dosing, which the Committee considered may result in improved treatment adherence over the required 12-month post-ACS treatment period.</p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence tabled in the HOST_REDUCE POLYTECH_ACS trial was impressive, demonstrating non-inferior primary efficacy with a significant reduction in on-treatment bleeding. However, the Committee noted that this was an open-label trial and that it was conducted on an East Asian population (Korean), and its results may or may not be realised in a New Zealand population to the same degree. </p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that both trials used objective endpoints of death, myocardial infarction (MI) and stroke. It was observed by some Members of the Committee that the period of the trials was only 12 months; however it was noted that there was no strong evidence available to support continued post-ACS dual anti-platelet therapy (DAPT) past 12 months.</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that most prescribers would likely favour the use of prasugrel over ticagrelor should it be made available on the Pharmaceutical Schedule.</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Advisory Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for prasugrel if it were to be funded in New Zealand for the treatment of acute coronary syndrome (ACS), ST elevation myocardial infarct or non-ST elevation myocardial infarct (STEMI or non-STEMI). This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000CNY3p&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000002ZNIl"" alt=""image.png""></img></p>', 'Status_History__c': 'a132P000000EDAcQAO'}, 'change': None}]",Dec 2020,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2022', 'fs': 'Oct 2022', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CNY3q2AH'}, 'Id': 'a0POZ00000CNY3q2AH', 'Event_Date__c': '2022-10-30', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Oct 2022', 'Status_History__c': 'a132P000000EDabQAG'}, 'change': None}]",Oct 2022,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2024', 'fs': 'Sep 2024', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CNY3r2AH'}, 'Id': 'a0POZ00000CNY3r2AH', 'Event_Date__c': '2024-09-09', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Sep 2024', 'Status_History__c': 'a13OZ00000E40w9YAB'}, 'change': None}]",Sep 2024,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
